Evaxion Biotech A/S saw its shares surge more than 27% Thursday after announcing that Merck & Co. has exercised its option to license the Danish biotech's vaccine candidate EVX-B3. The Nasdaq-listed stock climbed to $4.20, gaining $0.79 from its previous close of $3.30, with trading volume spiking to 71.4 million shares—far exceeding its average volume of approximately 92,000...
